OraSure Technologies, Inc. announced the acquisition of Sherlock Biosciences, Inc., a global health company focused on next-generation diagnostics. This acquisition significantly expands OraSure’s innovation pipeline by adding Sherlock’s molecular diagnostics platform, which is designed to provide rapid results with high sensitivity and specificity in a disposable format suitable for over-the-counter usage.
Sherlock’s initial molecular self-test targets Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), which will broaden OraSure’s portfolio of rapid diagnostics for sexually transmitted infections. This CT/NG self-test is currently in clinical studies and is expected to be submitted to the FDA by the end of 2025 for review, with test results anticipated in under 30 minutes.
OraSure estimates the total addressable market for CT/NG testing to be more than $1.5 billion, with the introduction of an affordable, rapid self-test having the potential for significant incremental market expansion. Revenue from Sherlock’s CT/NG test is expected to contribute to OraSure’s growth starting in 2026, leveraging OraSure’s existing commercial infrastructure and customer relationships.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.